BERKELEY, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

BERKELEY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed NV (NASDAQ: MYNZ - Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest totaling 255,354 shares, an increase of 47.4% from the December 31st total of 173,183 shares. Currently, 2.8% of the shares of the company are

BERKELEY, Calif. and , Jan. 14, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Speculative investors and patience rarely go hand in hand. Nevertheless, if you're looking to invest in the small-cap biotech sector, patience is a requirement.

Mainz Biomed NV (NASDAQ: MYNZ - Get Free Report)'s stock price fell 5.8% during mid-day trading on Friday. The company traded as low as $0.92 and last traded at $0.9990. 283,999 shares traded hands during trading, a decline of 68% from the average session volume of 897,663 shares. The stock had previously closed at $1.06.

BERKELEY, Calif. and MAINZ, Germany, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

BERKELEY, Calif. and MAINZ, Germany, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces positive topline results from its feasibility study, examining a non-invasive blood-based screening test for the early detection of pancreatic cancer, initiated earlier this year.